Purple Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cost of Revenue	-	0.06	0.2	0.12	0.06
Gross Profit	-	-0.06	-0.2	-0.12	-0.06
Selling, General & Admin	3.25	3.12	5.04	6.16	6.04
Research & Development	3.73	7.62	17.03	16.32	11.83
Operating Expenses	6.98	10.74	22.08	22.48	17.87
Operating Income	-6.98	-10.8	-22.27	-22.6	-17.92
Interest Expense	-0.98	-	-	-	-
Interest & Investment Income	-	0.26	0.47	0.53	0.32
Currency Exchange Gain (Loss)	-	-0.01	-0.01	0.06	-0.13
Other Non Operating Income (Expenses)	1.95	3.48	1.83	0.25	-0.08
EBT Excluding Unusual Items	-6.01	-7.08	-19.98	-21.76	-17.81
Asset Writedown	-20.48	-0.2	-	-	-
Legal Settlements	-	-	-	-	-0.01
Pretax Income	-26.49	-7.28	-19.98	-21.76	-17.83
Earnings From Continuing Operations	-26.49	-7.28	-19.98	-21.76	-17.83
Earnings From Discontinued Operations	-	-	-	-	-0.64
Net Income to Company	-26.49	-7.28	-19.98	-21.76	-18.47
Minority Interest in Earnings	0.11	0.04	0.1	0.09	0.08
Net Income	-26.39	-7.24	-19.88	-21.67	-18.38
Net Income to Common	-26.39	-7.24	-19.88	-21.67	-18.38
Shares Outstanding (Basic)	960	328	221	181	176
Shares Outstanding (Diluted)	960	328	221	181	176
Shares Change (YoY)	192.75%	48.17%	22.41%	2.92%	52.76%
EPS (Basic)	-0.03	-0.02	-0.09	-0.12	-0.10
EPS (Diluted)	-0.03	-0.02	-0.09	-0.12	-0.10
Free Cash Flow	-5.66	-14.37	-19.93	-16.76	-15.37
Free Cash Flow Per Share	-0.01	-0.04	-0.09	-0.09	-0.09
EBITDA	-6.77	-10.77	-22.23	-22.4	-17.69
D&A For EBITDA	0.2	0.03	0.05	0.2	0.23
EBIT	-6.98	-10.8	-22.27	-22.6	-17.92

Source: S&P Global Market Intelligence. Standard template. Financial Sources.